Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.

PURPOSE: To define the biology driving the aggressive nature of breast cancer arising in young women. EXPERIMENTAL DESIGN: Among 784 patients with early stage breast cancer, using prospectively-defined, age-specific cohorts (young or=65 years), 411 eligible patients (n = 200or=65 years) with clinically-annotated Affymetrix microarray data were identified. GSEA, signatures of oncogenic pathway deregulation and predictors of chemotherapy sensitivity were evaluated within the two age-defined cohorts. RESULTS: In comparing deregulation of oncogenic pathways between age groups, a higher probability of PI3K (p = 0.006) and Myc (p = 0.03) pathway deregulation was observed in breast tumors arising in younger women. When evaluating unique patterns of pathway deregulation, a low probability of Src and E2F deregulation in tumors of younger women, concurrent with a higher probability of PI3K, Myc, and beta-catenin, conferred a worse prognosis (HR = 4.15). In contrast, a higher probability of Src and E2F pathway activation in tumors of older women, with concurrent low probability of PI3K, Myc and beta-catenin deregulation, was associated with poorer outcome (HR = 2.7). In multivariate analyses, genomic clusters of pathway deregulation illustrate prognostic value. CONCLUSION: Results demonstrate that breast cancer arising in young women represents a distinct biologic entity characterized by unique patterns of deregulated signaling pathways that are prognostic, independent of currently available clinico-pathologic variables. These results should enable refinement of targeted treatment strategies in this clinically challenging situation.

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.

BACKGROUND: A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. This emphasizes the need to evaluate every patient's probability of responding to each chemotherapeutic agent and limiting the agents used to those most likely to be effective. METHODS AND RESULTS: Using gene expression data on the NCI-60 and corresponding drug sensitivity, mRNA and microRNA profiles were developed representing sensitivity to individual chemotherapeutic agents. The mRNA signatures were tested in an independent cohort of 133 breast cancer patients treated with the TFAC (paclitaxel, 5-fluorouracil, adriamycin, and cyclophosphamide) chemotherapy regimen. To further dissect the biology of resistance, we applied signatures of oncogenic pathway activation and performed hierarchical clustering. We then used mRNA signatures of chemotherapy sensitivity to identify alternative therapeutics for patients resistant to TFAC. Profiles from mRNA and microRNA expression data represent distinct biologic mechanisms of resistance to common cytotoxic agents. The individual mRNA signatures were validated in an independent dataset of breast tumors (P = 0.002, NPV = 82%). When the accuracy of the signatures was analyzed based on molecular variables, the predictive ability was found to be greater in basal-like than non basal-like patients (P = 0.03 and P = 0.06). Samples from patients with co-activated Myc and E2F represented the cohort with the lowest percentage (8%) of responders. Using mRNA signatures of sensitivity to other cytotoxic agents, we predict that TFAC non-responders are more likely to be sensitive to docetaxel (P = 0.04), representing a viable alternative therapy. CONCLUSIONS: Our results suggest that the optimal strategy for chemotherapy sensitivity prediction integrates molecular variables such as ER and HER2 status with corresponding microRNA and mRNA expression profiles. Importantly, we also present evidence to support the concept that analysis of molecular variables can present a rational strategy to identifying alternative therapeutic opportunities.

Entry and competition in generic biologics

Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologies can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which are manufactured through chemical synthesis, biologies are manufactured through fermentation, a process that is more variable and costly. Regulators might require extensive clinical testing of generic biologies to demonstrate equivalence to the branded product. The focus of the debate on generic biologies has been on legal and health concerns, but there are important economic implications. We combine a theoretical model of generic biologies with regression estimates from generic pharmaceuticals to estimate market entry and prices in the generic biologic market. We find that generic biologies will have high fixed costs from clinical testing and from manufacturing, so there will be less entry than would be expected for generic pharmaceuticals. With fewer generic competitors, generic biologies will be relatively close in price to branded biologies. Policy makers should be prudent in estimating financial benefits of generic biologies for consumers and payers. We also examine possible government strategies to promote generic competition. Copyright © 2007 John Wiley & Sons, Ltd.

Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer

Purpose: This study was designed to test the activity and feasibility of an all-oral regimen of levo-leucovorin and doxifluridine (dFUR) in the treatment of advanced colorectal cancer and to establish whether the pharmacokinetics of dFUR and fluorouracil (FU) are affected by demographic and/or biologic parameters. Materials and Methods: One hundred eight patients with histologically proven colorectal cancer received orally administered levo-leucovorin 25 mg followed 2 hours later by dFUR 1,200 mg/m2 on days 1 to 5, with the cycle being repeated every 10 days. Results: Among 62 previously untreated patients, two complete responses (CRs) and 18 partial responses (PRs) were observed (overall response rate, 32%; 95% confidence interval, 21% to 45%). The median response duration was 4 months (range, 2 to 13) and the median survival time, 14 months. Among 46 pretreated patients, there were three CRs and three PRs (response rate, 13%; 95% confidence interval, 5% to 26%). In this group of patients, the median response duration was 4 months (range, 1 to 12) and the median survival time, 12 months. No toxic deaths were observed. The only World Health Organization (WHO) grade 3 to 4 side effect was diarrhea (32 patients). Conclusion: This regimen is active in previously untreated colorectal cancer patients and combines good compliance with safety. Limited but definite efficacy was also detected in the patients previously treated with FU, which suggests incomplete cross- resistance between the two drugs. The pharmacokinetic results suggest that the conversion rate of dFUR to FU increases between days 1 and 5, but that FU levels remain low in comparison to those measured after classical FU therapy. Under the experimental conditions used in this study, the interpatient variability of pharmacokinetic parameters remains largely unexplained by the tested variables.

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma

BACKGROUND. Laboratory data suggest that insulin-like growth factor-1 (IGE-1) may stimulate the growth of different human tumors. At least in acromegalic patients, somatostatin (SMS) analogs, such as lanreotide, suppress the serum levels of growth hormone (GH) and IGE-1. METHODS. To evaluate the tolerability and biologic activity of different doses of lanreotide in patients with advanced colorectal carcinoma, consecutive groups of 3 patients each were subcutaneous treated with lanreotide at doses of 1, 2, 3, 4, 5, or 6 mg three times a day for 2 months. In the event of Grade 3 side effects, 3 additional patients were treated with the same dose before the next dose escalation. Serum samples were obtained on Days 0, 15, 30, and 60 for serum GH, IGF-1, and lanreotide assessment. RESULTS. Twenty-four patients were enrolled and all were evaluable. Except for the 3 and 6 mg doses, for which the observation of a Grade 3 side effect required that an additional three patients be treated, it was sufficient to treat 3 patients at each dose. The overall incidence of side effects was as follows: changes in bowel habits, 83%; abdominal cramps, 79%; diarrhea, 17%; vomiting, 17%; nausea, 21%; steatorrhea, 78%; hyperglycemia, 35%; laboratory hypothyroidism, 39%; gallstones, 13%; and weight loss, 17%. No evidence of an increase in the incidence, intensity, or duration of side effects was observed with dose escalation. Serum IGF-1 levels were as follows: Day 13: 63%, 60%, and 67% of the baseline values for the low (12 mg), intermediate (3-4 mg), and high (5- 6 mg) dose groups, respectively; Day 30: 63%, 59%, and 51%, respectively; and Day 60: 73%, 69%, and 47%, respectively. Serum lanreotide levels declined during treatment in all of the dose groups (90 ng/mL on Day 15, and 35 ng/mL on Day 60 for the 5-6 mg group; 10 ng/mL on Day 15, and 1.5 ng/mL on Day 60 for the 1-2 mg group). No antitumor activity or tumor marker reduction was observed. CONCLUSIONS. No increase in toxicity was observed when subcutaneous lanreotide doses were escalated to 6 mg three times a day for 2 months. The highest doses seemed to maintain reduced serum IGF-1 levels; with the lowest doses, a 'rebound' in serum IGF-1 levels was observed during treatment. Nevertheless, intermittent subcutaneous injections do not ensure constant serum drug concentrations over time.

Rheumatologists' judgements about the efficacy of anti-TNF therapy in two neighbouring regions

Objectives: The requirement in Northern Ireland to prescribe biologic agents according to NICE/BSR guidelines and within a fixed budget has created a waiting list for treatment that has no parallel in the Republic of Ireland. The study investigated the bearing this situation may have on had on the consultants’ judgements in the respective areas.

Methods: 78 case vignettes created from the data on real patients with RA treated with biologics in the north and south of Ireland were appraised by 9 southern and 8 northern consultants who judged the clinical benefit and significance of the patients’ condition after a trial of therapy. Quantitative (Clinical Judgement Analysis) and Qualitative (Focus groups) techniques were used.

Results: Northern consultants perceived a slightly greater degree of clinical benefit after a trial of therapy than southern consultants. Judgment models of northern and southern consultants were broadly comparable. The latter tended to be more uniform in their judgments than the southern group. Focus group discussions with consultants largely validated the findings of the quantitative analysis but revealed how clinical judgment analysis might be misled by gaming strategies.

Conclusions: Despite the absence of overt rationing in the south of Ireland, as far as the judgment of therapeutic benefit from biologics was concerned, the clinical judgment policies of practitioners were very similar to those in the north. The adoption of NICE/BSR guidelines in the north may have improved the uniformity of clinical practice in Northern Ireland.

Genetically Determined Height and Coronary Artery Disease

Background: The nature and underlying mechanisms of an inverse association between adult height and the risk of coronary artery disease (CAD) are unclear. 
Methods: We used a genetic approach to investigate the association between height and CAD, using 180 height-associated genetic variants. We tested the association between a change in genetically determined height of 1 SD (6.5 cm) with the risk of CAD in 65,066 cases and 128,383 controls. Using individual-level genotype data from 18,249 persons, we also examined the risk of CAD associated with the presence of various numbers of height-associated alleles. To identify putative mechanisms, we analyzed whether genetically determined height was associated with known cardiovascular risk factors and performed a pathway analysis of the height-associated genes. 
Results: We observed a relative increase of 13.5% (95% confidence interval [CI], 5.4 to 22.1; P<0.001) in the risk of CAD per 1-SD decrease in genetically determined height. There was a graded relationship between the presence of an increased number of height-raising variants and a reduced risk of CAD (odds ratio for height quartile 4 versus quartile 1, 0.74; 95% CI, 0.68 to 0.84; P<0.001). Of the 12 risk factors that we studied, we observed significant associations only with levels of low-density lipoprotein cholesterol and triglycerides (accounting for approximately 30% of the association). We identified several overlapping pathways involving genes associated with both development and atherosclerosis. 
Conclusions: There is a primary association between a genetically determined shorter height and an increased risk of CAD, a link that is partly explained by the association between shorter height and an adverse lipid profile. Shared biologic processes that determine achieved height and the development of atherosclerosis may explain some of the association. (Funded by the British Heart Foundation and others.)

Asthma control and exacerbations: two different sides of the same coin.

Purpose of review: Optimal asthma management includes both the control of asthma symptoms and reducing the risk of future asthma exacerbations. Traditionally, treatment has been adjusted largely on the basis of symptoms and lung function and for many patients, this approach delivers both excellent symptom control and reduced risk. However, the relationship between these two key components of the disease may vary between different asthmatic phenotypes and disease severities and there is increasing recognition of the need for more individualized treatment approaches.

Recent findings: A number of factors which predict exacerbation risk have been identified including demographic and behavioural features and specific inflammatory biomarkers. Type-2 cytokine-driven eosinophilic airways inflammation predisposes to frequent exacerbations and predicts response to corticosteroids, and the usefulness of sputum eosinophilia as both a marker of exacerbation risk and biomarker for adjustment of corticosteroid treatment has been established for some time. However, attempts to develop surrogate markers, which would be more straightforward to deliver in the clinic, have been challenging.

Summary: Some patients with asthma have persistent symptoms in the absence of type-2 cytokine driven-eosinophilic airways inflammation due to noncorticosteroid responsive mechanisms (T2-low disease). Composite biomarker strategies using easily measured surrogate indicators of type-2 inflammation (such as fractional exhaled nitric oxide, blood eosinophil count and serum periostin levels) may predict exacerbation risk better but it is unclear if they can be used to adjust corticosteroid treatment. Biomarkers will be used to target novel biologic treatments but additionally may be used to optimize corticosteroid treatment dose and act as prognostics for exacerbation risk and potentially other important longer term asthma outcomes.

Carcinoma da nasofaringe: aspectos epidemiológicos clínicos e moleculares

Após uma revisão de aspectos filogénicos, ontogénicos e embriológicos contribuindo para a estruturação anatómica e fisiológica da nasofaringe, é efectuada uma análise das características clínicas do carcinoma da nasofaringe numa população portuguesa, comparando-as com a literatura. É efectuada análise de taxa de incidência da doença, razão de géneros, frequência relativa dos diversos subtipos de acordo com a classificação OMS, acuidade relativa dos estadiamentos TMN e sobrevivência em função do tratamento. A relação entre carcinoma da nasofaringe e infecção pelo vírus de Epstein – Barr em Portugal é estudada através da análise de detecção de DNA de EBV em tecido tumoral da nasofaringe e sangue periférico de doentes com NPC e em indivíduos saudáveis. São também efectuados estudos caso-controlo no sentido de perspectivar a relevância de dois polimorfismos genéticos na susceptibilidade genética para a doença. Esta Dissertação pretende ainda contribuir para a compreensão dos mecanismos biológicos de CN e a sua relação com o EBV numa região não endémica de baixo risco, como é Portugal, realçando a relevância da definição de um perfil biológico preditivo para o desenvolvimento de CN na população portuguesa.

Maturação de lamas vulcânicas açorianas e sua aplicação em peloterapia

Em Portugal, nomeadamente nos Açores (Centro Termal das Furnas), durante vários anos foram utilizados pelóides naturais (lamas/argilas obtidos após conveniente maturação com água mineral) como agentes terapêuticos. Apesar das evidências empíricas da aplicação das argilas para fins terapêuticos, o suporte científico é ainda escasso. Além disso, contrariamente ao que se verifica para águas minerais utilizadas para fins termais, no campo da peloterapia, não existe regulamentação que estabeleça critérios quanto à qualidade padrão de um pelóide. Este trabalho visou a avaliação das características biológicas, físico-químicas e mineralógicas de lamas vulcânicas das ilhas de São Miguel e da Terceira para aplicação em peloterapia antes e após maturação. A área de amostragem foi caracterizada sob o ponto de vista geomorfológico, geológico, hidrológico e climático. A análise dos materiais colhidos contemplou estudos de granulometria e de mineralogia da amostra total e da fracção argilosa; caracterização química; e determinação de outras propriedades tais como índice de abrasividade, superfície específica, pH, capacidade de troca catiónica e catiões de troca, limites de consistência (plasticidade e liquidez e índice de plasticidade) e taxa de arrefecimento. A caracterização biológica das lamas incluiu a identificação e quantificação relativa de diatomáceas e a determinação do teor em coliformes totais e microrganismos cultiváveis a 37 ºC e a 22 ºC. Estudos efectuados em amostras comerciais argilosas e em recursos naturais açorianos precederam os ensaios de maturação. Estes estudos visaram, fundamentalmente, aferir as características apropriadas dos materiais para aplicação tópica e detectar e caracterizar a presença de comunidades diatomológicas em locais próximos dos materiais a serem sujeitos a maturação. O estudo de maturação foi desenvolvido em duas etapas sequenciais e complementares com vista à optimização do processo de maturação de lamas vulcânicas açorianas. Foi testada a influência de algumas condições abióticas na maturação e fez-se variar a fracção granulométrica, proporção fase sólida:fase líquida e o tempo de maturação entre os dois ensaios. O uso da granulometria <63 μm, proporção de 2:1 (fase sólida:fase líquida) e condições de luminosidade, sem agitação parecem ser as mais adequadas à maturação dos materiais analisados. A maturação revela-se um processo que promove a melhoria de características importantes dos materiais para aplicação em peloterapia, tais como aumento dos tempos de arrefecimento e da quantidade de catiões de troca. Existe uma comunidade de microalgas e bacteriana capaz de se desenvolver em materiais geológicos vulcânicos durante a maturação e cujo contributo para a acção terapêutica do pelóide deverá ser aferida. Após comparação com materiais de referência, a amostra das Furnas revela as características mais adequadas para aplicação em peloterapia.

Obesidade infantil: práticas alimentares e percepção materna de competências

A obesidade infantil é um importante problema de saúde pública, não só pelos efeitos adversos durante a infância mas porque tende a persistir na idade adulta, constituindo um factor de risco para diversas doenças crónicas. Os alicerces de uma vida saudável estruturam-se na vida pré-natal e sedimentam-se nos seis primeiros anos de vida, sendo o crescimento da criança fortemente influenciado pelo seu contexto ambiental familiar. Foi neste âmbito que emergiu como objectivo geral deste estudo explorar as relações existentes entre os determinantes infantis (antecedentes obstétricos e peri-natais) e parentais (práticas alimentares, conhecimento dos pais sobre alimentação infantil, percepção parental de competência e percepção do peso da criança) e o desenvolvimento de excesso de peso em crianças pré-escolares. Este estudo, de carácter observacional e transversal, foi realizado com 792 crianças pré-escolares, idade M= 4,39 anos (±0,91Dp) e seus pais, residentes num concelho pertencente às NUTs III Dão-Lafões, sendo efectuada a avaliação antropométrica e classificação nutricional das crianças com base no referencial NCHS (CDC, 2000) e da OMS nos pais. O protocolo de pesquisa incluiu instrumentos de medida que validamos para a população portuguesa e a construção do Questionário de Conhecimentos sobre Alimentação Infantil (QAI) cujas propriedades psicométricas certificam a sua qualidade (Alfa de Cronbach = 0,942; Alfa de Cronbach teste re-teste = 0,977). Nas crianças, 31,3% apresentavam excesso de peso (12,4% obesidade), assim como 41,1% das mães (10,2% obesidade) e 64,4% dos pais (14,8% obesidade), sendo mais evidente nas mães o risco metabólico associado ao Perímetro da Cintura. As mães revelam mais conhecimentos sobre alimentação e sentimentos de eficácia mais elevados com o papel parental, enquanto os pais manifestaram mais sentimentos de motivação e satisfação. Os resultados obtidos corroboram existir efeito significativo dos determinantes infantis e parentais no excesso de peso da criança, designadamente: (i) do peso ao nascer, com impacto dos nascidos grandes; (ii) da higiene do sono especificamente dos que dormem menos de 11horas; (iii) dos que não brincam na rua, (iv) das mães mais jovens, do IMC e risco metabólico dos Pais; (v) da percepção parental da imagem corporal dos filhos, verificando-se que quanto mais elevado o IMC das crianças, mais distorcida é esta percepção dos pais; (vi) das crenças, atitudes e práticas alimentares e que permitem inferir que uma maior preocupação com o peso da criança, maior controlo, restrição e menor pressão para comer se associa a maior excesso de peso. As inferências evidenciam que, na vigilância de saúde periódica se torna imprescindível a valorização dos determinantes de risco biológicos e familiares do excesso de peso infantil, considerando programas de intervenção centrados na família, num processo que encontre sentido a partir daquilo que as famílias experienciam, de forma a ajudá-las a criar recursos fortalecedores de competência para uma parentalidade mais positiva.

EU water framework directive: will the nitrate load reduction from diffuse sources produce the same results in all estuaries?

The impact of urban waste-water and non-point nitrate discharges in estuarine and near-shore coastal waters are analyzed. The study is focused on the effects of applying the European directives 91/271/EEC and 91/676/EEC to these systems. 4 Portuguese estuaries and two coastal lagoons with different characteristics are studied. A modelling system is applied and calibrated in each system. Three nitrate load scenarios are examined. It is shown that the morphologic and hydrodynamic characteristics of the domain largely control the ecological processes in these systems. The primary production limitation factors are split into “biologic” and “hydrodynamic” components. The physical limitation due to hydrodynamic and residence time is the most important factor. The combined limitation of “biologic” factors (temperature, light and nutrients availability) control productivity only in the systems where physical limitation is not important.

Aplication of a morphodinamic process based model in long-term climate change studies

Climate changes are foreseen to produce a large impact in the morphology of estuaries and coastal systems. The morphology changes will subsequently drive changes in the biologic compartments of the systems and ultimately in their ecosystems. Sea level rise is one of the main factors controlling these changes. Morphologic changes can be better understood with the use of long term morphodynamic mathematical models.

Distribuição e padrões de utilização das conchas de caranguejos eremitas (Anomura) da Costa do Algarve

Dissertação mest., Biologia Marinha - Ecologia e Conservação Marinha, Universidade do Algarve, 2008

Évaluation de l’impact de pansements biologiques humains produits par génie tissulaire sur la guérison de plaies cutanées murines

L’étude de la guérison des plaies à l’aide de substituts produits par génie tissulaire est un domaine en plein essor. Dans ces travaux, les effets de pansements biologiques produits en laboratoire à partir de cellules souches/stromales du tissu adipeux (CSTA) différenciées ou non en adipocytes ont été évalués sur des plaies cutanées in vivo. Un modèle de souris possédant un épiderme fluorescent a permis de démontrer que les plaies traitées avec les pansements biologiques guérissent plus rapidement que les plaies non traitées, et ce, de manière indépendante de la réépithélialisation. Une augmentation de la formation du tissu de granulation et une angiogenèse accrue ont également été observées dans les groupes traités. Ces résultats établissent que les substituts contenant des CSTA ou des adipocytes fonctionnels favorisent la réparation tissulaire. À terme, ces travaux pourraient mener au développement de nouvelles indications cliniques pour le traitement des ulcères cutanés.